

COVID-19 Vaccine Decision Tree For Adults Ages 18 Years or Older

This document includes COVID-19 vaccination guidance for healthy* adults ages 18 years or older.

Primary Series for Adults Ages 18 years +PAGE 2


Bivalent Booster Dose for Adults Ages 18 years +PAGE 3

AVAILABLE COVID-19 VACCINES:

- **PFIZER-BIONTECH:**
 - 12+ years (primary series, additional dose)
 - 12+ years (bivalent booster dose)
- **MODERNA:**
 - 18+ years (primary series, additional dose)
 - 18+ years (bivalent booster dose)
- **NOVAVAX**
 - 12+ years (primary series)
- **JOHNSON & JOHNSON**
 - **The CDC recommends the preferred use of mRNA (Pfizer or Moderna) COVID-19 vaccines whenever feasible. However, a patient may receive a Johnson & Johnson COVID-19 vaccine in certain situations.**
 - 18+ years (primary dose, booster dose)

***This resource does NOT include information pertaining to individuals who are moderately or severely immunocompromised (weakened immune system) and are authorized for an additional primary series dose.** For more information regarding COVID-19 primary series vaccination for those who are moderately or severely immunocompromised please reference the NDHHS *COVID-19 Vaccine Decision Tree: Primary Series for those who are Immunocompromised* or visit the [CDC's COVID-19 vaccine clinical considerations for those who are moderately to severely immunocompromised](#) website.


THE FOLLOWING INFORMATION IS SUBJECT TO CHANGE AS NEW INFORMATION BECOMES AVAILABLE. PLEASE CHECK THE CDC'S INTERIM CLINICAL CONSIDERATIONS FOR COVID-19 VACCINES TO ENSURE YOU ARE VACCINATING PATIENTS USING THE MOST RECENTLY UPDATED GUIDANCE.



This guidance does NOT apply to individuals who are moderately or severely immunocompromised³ (weakened immune system) and are authorized for an additional primary series dose⁴. For more information regarding COVID-19 primary series vaccination for those who are moderately or severely immunocompromised please reference the NDHHS *COVID-19 Vaccine Decision Tree: Primary Series for those who are Immunocompromised* or visit the [CDC's COVID-19 vaccine clinical considerations for those who are moderately to severely immunocompromised](#) website.

COVID-19 Vaccine Decision Tree

Booster Dose for Adults Ages 18+



For more information on bivalent booster dose recommendations, please visit the CDC's [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) website.

¹IMPORTANT: All individuals are recommended to receive a primary vaccination series, booster dose, and/or additional dose of an mRNA COVID-19 vaccine (Pfizer or Moderna) over the use of the Janssen (Johnson & Johnson) COVID-19 vaccine. As of May 5, 2022, the Johnson & Johnson COVID-19 vaccine is no longer authorized by the U.S. Food & Drug Administration (FDA) for use in all adults ages 18 years or older. However, select populations may still receive the Johnson & Johnson COVID-19 vaccine. These individuals should talk to a trusted healthcare provider prior to receiving this vaccine. Patients requesting this vaccine must be informed on the potential risks associated with the Johnson & Johnson vaccine. This change in guidance comes after reviewing data finding an increased risk of Thrombosis with Thrombocytopenia associated with those who have received the Janssen COVID-19 vaccine.

²Primary series dose volumes are as follows:

- Pfizer (ages 12+) 0.3mL
- Moderna (ages 18+) 0.5mL
- Novavax (ages 12+) 0.5mL
- In certain situations, some individuals may choose to receive a primary dose of Johnson & Johnson (ages 18+) 0.5mL

Booster dose volumes are as follows:

- Pfizer (ages 12+) 0.3mL
- Moderna (ages 18+) 0.5 mL

³CDC updated the Interim Clinical Considerations for COVID-19 Vaccination Guidance with additional information to help vaccine providers determine if an individual patient's optimal interval between their 1st dose and 2nd dose in a primary series should be extended by up to 8 weeks rather than the previously recommended 3-week (Pfizer-BioNTech or Novavax) or 4-week (Moderna) intervals. Some **people ages 6 months through 64 years – and especially males ages 12 through 39 years** – may benefit from getting their second mRNA COVID-19 vaccine dose 8 weeks after receiving their first dose. Please talk to your healthcare or vaccine provider about the timing of the second dose that is right for you. **IMPORTANT:** A shorter interval (3 weeks for Pfizer-BioNTech and Novavax; 4 weeks for Moderna) between the first and second doses remains the recommended interval for people who are...

- moderately or severely immunocompromised individuals ages 6 months and older,
- adults ages 65 years and older,
- and in situations in which there is increased concern about [COVID-19 community levels](#), or
- when an individual is at higher risk for severe disease due to COVID-19.

⁴Moderately or severely immunocompromised individuals are authorized to receive an additional dose of COVID-19 vaccine at least 28 days after the completion of their primary series. The CDC defines moderately or severely immunocompromised as individuals who have:

- Been receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency (such as DiGeorge syndrome, Wiskott-Aldrich syndrome)
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response

For more information regarding COVID-19 booster doses for those who are moderately or severely immunocompromised please reference the NDHHS COVID-19 Vaccine Decision Tree: Booster Dose for those who are Immunocompromised.

As of September 1, 2022, the CDC has recommended that everyone 12 years and older should receive a bivalent booster dose at least 2 months after their first booster dose including: For more information, please visit the CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines [webpage](#).